Study: Macrolide antibiotics may benefit non-CF bronchiectasis patients

Azithromycin and erythromycin significantly decreased the number of pulmonary exacerbations in patients with non-cystic fibrosis bronchiectasis, but long-term use increased resistance to the drugs, according to two studies in the Journal of the American Medical Association. Azithromycin and erythromycin enhanced lung function, while azithromycin significantly improved quality of life.

View Full Article in:

PhysiciansBriefing.com · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD